Indo US Bio-Tech Ltd. | Small-cap | Basic Materials
₹142.78
-0.19%
| Indo US Bio-Tech Stock Comparison:
Indo US Bio-Tech vs CoromandelIndo US Bio-Tech vs UPLIndo US Bio-Tech vs National FertilizersIndo US Bio-Tech vs NACL IndustriesIndo US Bio-Tech vs Bharat RasayanIndo US Bio-Tech vs NIFTY 50 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 333.8M
Gross Profit 89.7M 26.88%
Operating Income 40.2M 12.04%
Net Income 36.8M 11.04%

Balance Sheet Metrics

Total Assets 978.4M
Total Liabilities 193.2M
Shareholders Equity 785.2M
Debt to Equity 0.25

Cash Flow Metrics

Revenue & Profitability Trend

Indo US Bio-Tech Income Statement From 2021 to 2025

Metric20252024202320222021
Revenue i1.0B728.4M617.4M500.6M401.1M
Cost of Goods Sold i726.6M493.7M457.4M368.3M271.5M
Gross Profit i311.8M234.6M160.0M132.3M129.6M
Gross Margin % i30.0%32.2%25.9%26.4%32.3%
Operating Expenses
Research & Development i-54.9M17.2M20.3M20.8M
Selling, General & Administrative i-20.1M19.8M16.3M26.5M
Other Operating Expenses i111.5M115.0M5.8M17.6M23.6M
Total Operating Expenses i111.5M190.0M42.8M54.2M70.9M
Operating Income i178.4M99.8M94.9M66.6M51.1M
Operating Margin % i17.2%13.7%15.4%13.3%12.8%
Non-Operating Items
Interest Income i-122.2K025.6K16.7K
Interest Expense i14.9M15.1M11.2M11.4M11.2M
Other Non-Operating Income-----
Pre-tax Income i165.3M87.9M73.9M53.1M39.3M
Income Tax i2.6M5.5M1.5M2.5M-9.7M
Effective Tax Rate % i1.6%6.3%2.0%4.7%-24.7%
Net Income i162.7M82.4M72.4M50.6M49.0M
Net Margin % i15.7%11.3%11.7%10.1%12.2%
Key Metrics
EBITDA i191.2M111.0M93.4M71.7M53.4M
EPS (Basic) i₹8.12₹4.11₹7.51₹4.14₹3.36
EPS (Diluted) i₹8.12₹4.11₹7.51₹4.14₹3.36
Basic Shares Outstanding i200337442005012296446121223927414563176
Diluted Shares Outstanding i200337442005012296446121223927414563176

Income Statement Trend

Indo US Bio-Tech Balance Sheet From 2021 to 2025

Metric20252024202320222021
Assets
Current Assets
Cash & Equivalents i2.5M492.2K1.3M481.8K1.3M
Short-term Investments i-----
Accounts Receivable i150.0M205.5M247.1M205.5M247.1M
Inventory i706.9M233.6M118.8M233.6M118.8M
Other Current Assets381.0K1.0K-1469.0K-1
Total Current Assets i867.3M468.4M381.3M468.4M381.3M
Non-Current Assets
Property, Plant & Equipment i102.3M55.5M23.7M55.5M23.7M
Goodwill i-0000
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets1.9M-1144.3K-1144.3K
Total Non-Current Assets i111.2M87.8M55.7M87.8M55.7M
Total Assets i978.4M556.2M437.1M556.2M437.1M
Liabilities
Current Liabilities
Accounts Payable i11.6M28.2M94.5M27.0M89.4M
Short-term Debt i119.0M91.1M81.1M91.1M81.1M
Current Portion of Long-term Debt-----
Other Current Liabilities29.7M1-3.7M16.4M
Total Current Liabilities i163.4M122.8M180.9M122.8M180.9M
Non-Current Liabilities
Long-term Debt i29.3M37.3M34.5M37.3M34.5M
Deferred Tax Liabilities i-0-00
Other Non-Current Liabilities-14.0M-10.5M7.9M
Total Non-Current Liabilities i29.9M48.2M42.7M48.2M42.7M
Total Liabilities i193.2M171.1M223.6M171.1M223.6M
Equity
Common Stock i200.5M91.7M60.7M91.7M60.7M
Retained Earnings i-147.4M110.4M147.4M110.4M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i785.2M385.1M213.4M385.1M213.4M
Key Metrics
Total Debt i148.4M128.4M115.7M128.4M115.7M
Working Capital i703.9M345.5M200.4M345.5M200.4M

Balance Sheet Composition

Indo US Bio-Tech Cash Flow Statement From 2021 to 2025

Metric20252024202320222021
Operating Activities
Net Income i165.3M87.9M73.9M53.1M39.3M
Depreciation & Amortization i-----
Stock-Based Compensation i-----
Working Capital Changes i-145.3M-115.1M-78.0M-71.2M-60.8M
Operating Cash Flow i34.2M-12.1M7.8M-6.3M-9.7M
Investing Activities
Capital Expenditures i-8.6M-26.1M-18.2M-39.7M-19.4M
Acquisitions i-----
Investment Purchases i-----
Investment Sales i-099.0K--
Investing Cash Flow i-8.6M-25.4M-16.9M-39.7M-19.4M
Financing Activities
Share Repurchases i-----
Dividends Paid i-5.0M---1.5M-
Debt Issuance i1.3M11.0M-2.8M26.0M
Debt Repayment i---16.9M--
Financing Cash Flow i107.0K27.3M74.7M38.3M27.2M
Free Cash Flow i5.6M-3.9M-13.0M-12.6M-18.0M
Net Change in Cash i25.7M-10.2M65.6M-7.6M-1.9M

Cash Flow Trend

Indo US Bio-Tech Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 16.15
Price to Book 3.63
Price to Sales 2.63

Profitability Ratios

Profit Margin 16.20%
Operating Margin 17.13%
Return on Equity 20.72%
Return on Assets 16.63%

Financial Health

Current Ratio 5.31
Debt to Equity 18.90
Beta -0.65

Per Share Data

EPS (TTM) ₹8.91
Book Value per Share ₹39.64
Revenue per Share ₹54.88

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
indous2.9B16.153.6320.72%16.20%18.90
Coromandel 671.9B29.285.9618.41%8.56%6.95
UPL 620.3B3.001.632.01%0.09%105.06
National Fertilizers 48.8B31.631.796.77%0.84%73.68
NACL Industries 46.9B91.5411.22-21.57%-4.29%93.35
Bharat Rasayan 42.2B30.583.7212.47%10.84%7.54

Financial data is updated regularly. All figures are in the company's reporting currency.